Medicines for HER+ breast cancer

PheWeb

RX_HERPLUS

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC L02B[AG]

10576

Check pre-conditions, main-only, mode, ICD version None

7988

Check minimum number of events

Min. number of events 3

7988

Include endpoints None

7988

RX_HERPLUS

Extra metadata

First used in FinnGen datafreeze DF5

Similar endpoints

↥

List of similar endpoints to Medicines for HER+ breast cancer based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	7750	7631	119
Unadjusted prevalence (%)	2.51	4.40	0.09
Mean age at first event (years)	60.38	60.49	52.98

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.05	4.07 [3.09, 5.37]	2.8e-23	562
15 years	0.01	2.30 [1.74, 3.04]	4.1e-9	275
5 years	0.01	5.36 [4.23, 6.79]	1.2e-43	233
1 year	0.00	2.79 [1.78, 4.37]	7.7e-6	24

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: RX_HERPLUS – Medicines for HER+ breast cancer
GWS hits:

Survival analyses between endpoints

↥

Plot

before Medicines for HER+ breast cancer
after Medicines for HER+ breast cancer

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Medicines for HER+ breast cancer

↥